Last reviewed · How we verify
A-101 Solution
A-101 is a topical solution that induces controlled necrosis of skin lesions through a proprietary mechanism.
A-101 is a topical solution that induces controlled necrosis of skin lesions through a proprietary mechanism. Used for Seborrheic keratosis, Common warts, Molluscum contagiosum.
At a glance
| Generic name | A-101 Solution |
|---|---|
| Also known as | hydrogen peroxide 45% |
| Sponsor | Aclaris Therapeutics, Inc. |
| Drug class | Topical cytolytic agent |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
A-101 contains a high-concentration hydrogen peroxide formulation designed to selectively destroy targeted skin tissue. When applied topically, it creates a controlled chemical burn that leads to necrosis and sloughing of the lesion, allowing healthy skin to regenerate. The mechanism is distinct from traditional keratolytic agents and works through direct cytotoxic effects on the lesion tissue.
Approved indications
- Seborrheic keratosis
- Common warts
- Molluscum contagiosum
Common side effects
- Application site irritation
- Application site erythema
- Application site pain or burning
- Hyperpigmentation
- Hypopigmentation
Key clinical trials
- Biofeedback-VR for Treatment of Chronic Migraine (NA)
- Study of A-101 for the Treatment of Seborrheic Keratosis (PHASE2)
- Safety Study of A-101 Topical Solution for the Treatment of Common Warts (PHASE3)
- A Study of A-101 Topical Solution for the Treatment of Common Warts (PHASE3)
- Study of A-101 Topical Solution for the Treatment of Common Warts (PHASE3)
- A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra (PHASE2)
- An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses (PHASE4)
- A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- A-101 Solution CI brief — competitive landscape report
- A-101 Solution updates RSS · CI watch RSS
- Aclaris Therapeutics, Inc. portfolio CI